KPTI
Karyopharm Therapeutics Inc.
Overview
Karyopharm Therapeutics Inc is a Healthcare company operating in Biotechnology with a $204.0M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 10, 2026).
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-1413 Q&A exchanges
- Q4 FY2025Earnings2026-02-1214 Q&A exchanges
- Q3 FY2025Earnings2025-11-0310 Q&A exchanges
- Q2 FY2025Earnings2025-08-119 Q&A exchanges
- Q1 FY2025Earnings2025-05-1316 Q&A exchanges
- Q4 FY2024Earnings2025-02-1915 Q&A exchanges
- Q3 FY2024Earnings2024-11-0511 Q&A exchanges
- Q1 FY2024Earnings2024-05-0813 Q&A exchanges
- Q4 FY2023Earnings2024-02-2915 Q&A exchanges
- Q3 FY2023Earnings2023-11-0211 Q&A exchanges
- Q2 FY2023Earnings2023-08-0217 Q&A exchanges
- Q1 FY2023Earnings2023-05-0615 Q&A exchanges
- Q3 FY2022Earnings2022-11-0311 Q&A exchanges
- Q2 FY2022Earnings2022-08-0414 Q&A exchanges
- Q1 FY2022Earnings2022-05-0515 Q&A exchanges
- Q4 FY2021Earnings2022-02-0818 Q&A exchanges
- Q3 FY2021Earnings2021-11-0324 Q&A exchanges
- Q2 FY2021Earnings2021-08-0523 Q&A exchanges
- Q1 FY2021Earnings2021-05-0326 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-10EPS— vs $-1.39—Rev— vs ——EODHD
- Q1 FY20262026-05-13EPS$-1.24 vs $-1.44+13.9%Rev$35.1M vs ——EODHD
- Q4 FY20252026-02-11EPS$-2.23 vs $-2.00-11.5%Rev$34.1M vs ——EODHD
- Q3 FY20252025-11-02EPS$-3.82 vs $-3.25-17.5%Rev$44.0M vs ——EODHD
- Q2 FY20252025-08-10EPS$-4.07 vs $-3.91-4.1%Rev$37.9M vs ——EODHD
- Q1 FY20252025-05-11EPS$-2.77 vs $-3.09+10.4%Rev$30.0M vs ——EODHD
- Q4 FY20242025-02-18EPS$-3.60 vs $-4.03+10.7%Rev$30.5M vs ——EODHD
- Q3 FY20242024-11-04EPS$-3.90 vs $-3.92+0.5%Rev$38.8M vs ——EODHD
- Q2 FY20242024-08-05EPS$-4.34 vs $-4.47+2.9%Rev$42.8M vs ——EODHD
- Q1 FY20242024-05-07EPS$-4.80 vs $-4.94+2.8%Rev$33.1M vs ——EODHD
- Q4 FY20232024-02-28EPS$-0.36 vs $-0.31-16.1%Rev$33.7M vs ——EODHD
- Q3 FY20232023-11-01EPS$-4.50 vs $-4.29-4.9%Rev$36.0M vs ——EODHD
- Q2 FY20232023-08-01EPS$-4.35 vs $-5.04+13.7%Rev$37.6M vs ——EODHD
- Q1 FY20232023-05-03EPS$-4.50 vs $-5.23+14.0%Rev$38.7M vs ——EODHD
- Q4 FY20222023-02-14EPS$-6.45 vs $-5.38-19.9%Rev$33.6M vs ——EODHD
- Q3 FY20222022-11-02EPS$-6.75 vs $-8.02+15.8%Rev$36.1M vs ——EODHD
- Q2 FY20222022-08-03EPS$-9.30 vs $-9.55+2.6%Rev$39.7M vs ——EODHD
- Q1 FY20222022-05-04EPS$-7.95 vs $-9.24+14.0%Rev$47.7M vs ——EODHD
- Q4 FY20212022-02-07EPS$6.90 vs $-6.37+100.0%Rev$126.3M vs ——EODHD
- Q3 FY20212021-11-02EPS$-10.35 vs $-10.27-0.8%Rev$37.7M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-10 | — | $-1.39 | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-13 | $-1.24 | $-1.44 | +13.9% | $35.1M | — | — | EODHD |
| Q4 FY2025 | 2026-02-11 | $-2.23 | $-2.00 | -11.5% | $34.1M | — | — | EODHD |
| Q3 FY2025 | 2025-11-02 | $-3.82 | $-3.25 | -17.5% | $44.0M | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-4.07 | $-3.91 | -4.1% | $37.9M | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-2.77 | $-3.09 | +10.4% | $30.0M | — | — | EODHD |
| Q4 FY2024 | 2025-02-18 | $-3.60 | $-4.03 | +10.7% | $30.5M | — | — | EODHD |
| Q3 FY2024 | 2024-11-04 | $-3.90 | $-3.92 | +0.5% | $38.8M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $-4.34 | $-4.47 | +2.9% | $42.8M | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-4.80 | $-4.94 | +2.8% | $33.1M | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $-0.36 | $-0.31 | -16.1% | $33.7M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-4.50 | $-4.29 | -4.9% | $36.0M | — | — | EODHD |
| Q2 FY2023 | 2023-08-01 | $-4.35 | $-5.04 | +13.7% | $37.6M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-4.50 | $-5.23 | +14.0% | $38.7M | — | — | EODHD |
| Q4 FY2022 | 2023-02-14 | $-6.45 | $-5.38 | -19.9% | $33.6M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-6.75 | $-8.02 | +15.8% | $36.1M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-9.30 | $-9.55 | +2.6% | $39.7M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-7.95 | $-9.24 | +14.0% | $47.7M | — | — | EODHD |
| Q4 FY2021 | 2022-02-07 | $6.90 | $-6.37 | +100.0% | $126.3M | — | — | EODHD |
| Q3 FY2021 | 2021-11-02 | $-10.35 | $-10.27 | -0.8% | $37.7M | — | — | EODHD |
Source: EODHD. KPTI reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks KPTI's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.29 | $2.82 | +16.6% | -3.7% | -0.9% |
| Q4 FY2026 | $3.05 | $2.83 | +7.7% | +1.5% | +0.3% |
| Q3 FY2026 | $3.20 | $2.87 | +11.4% | -4.0% | -6.7% |
| Q2 FY2026 | $3.49 | $2.95 | +18.2% | -1.9% | +0.9% |
| Q1 FY2025 | $3.24 | $3.00 | +8.0% | -3.4% | -2.0% |
| Q4 FY2025 | $3.37 | $2.96 | +13.9% | +1.1% | -0.6% |
| Q3 FY2025 | $3.27 | $3.06 | +7.0% | -4.0% | -5.8% |
| Q2 FY2025 | $3.31 | $2.89 | +14.7% | +2.8% | +1.9% |
| Q1 FY2024 | $3.47 | $3.02 | +14.9% | +4.8% | +3.6% |
| Q4 FY2024 | $3.37 | $2.99 | +12.8% | -2.5% | -2.5% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Richard A PaulsonCEO9 mo19 callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • guidance suspended Q3 FY2026
- Lori MacomberCFO8 mo6 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last call held guidance Q3 FY2026
- Michael ManoEVP, CLO&Secretary5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2026 • 2/2 beats (100%) • last call held guidance Q2 FY2026
- Sohanya Roshan ChengEVP & Chief Commercial Officer9 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • last call held guidance Q3 FY2026
- Reshma RangwalaEVP & Chief Medical Officer9 mo15 callsCurrentSample
OTHER_C_SUITE since 2025 • 3/4 beats (75%) • guidance suspended Q3 FY2026
- Stuart PoultonEVP, Chief Development Officer11 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • guidance suspended Q1 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for KPTI.
$ curl https://api.spokenalpha.com/v1/companies/KPTIFAQ
Frequently asked about KPTI
Where can I find Karyopharm Therapeutics Inc.'s (KPTI) earnings call transcripts?
Spoken Alpha indexes KPTI's earnings call transcripts at https://spokenalpha.com/companies/KPTI. Each call links to attributed speakers and parsed analyst Q&A. Karyopharm Therapeutics Inc.'s own investor relations page is at https://investors.karyopharm.com/.
When was Karyopharm Therapeutics Inc.'s most recent earnings call?
Karyopharm Therapeutics Inc. (KPTI) held its most recent earnings call on 2026-05-14, covering fiscal Q1 2026.
What sector is KPTI in?
Karyopharm Therapeutics Inc. (KPTI) operates in the Healthcare sector (Biotechnology industry).